@Article{or.2026.079813,
AUTHOR = {Zhen Wang, Qian Xie, Yu Luo, Chuan Li, Wenqiang Guan, Yanling Zhang, Jidong Miao},
TITLE = {Factors Affecting the Efficacy and Safety of First-Line Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/26825},
ISSN = {1555-3906},
ABSTRACT = {<b>Objective:</b> This study assesses peripheral blood parameters as predictors of programmed cell death protein-1 (PD-1) inhibitor efficacy in advanced non-small cell lung cancer (NSCLC). <b>Methods:</b> We retrospectively analyzed 169 advanced NSCLC patients receiving first-line PD-1 inhibitor-based therapy. Baseline blood parameters and clinical characteristics were recorded. Logistic regression assessed associations with immune-related adverse events (irAEs). Chi-square tests compared efficacy and safety across treatment groups. <b>Results:</b> Baseline albumin/fibrinogen ratio (ALB/FIB) and PIV were associated with all-grade irAEs (<i>p</i> &lt; 0.05), while PIV was markedly associated with grade ≥3 irAEs (<i>p</i> &lt; 0.01). Multivariate analysis identified that the baseline pan-immune inflammation value (PIV) was independently associated with the occurrence of irAEs (<i>p</i> &lt; 0.01). Compared to PD-1 inhibitor plus chemotherapy, adding bevacizumab increased oral mucositis (<i>p</i> = 0.010) and was linked to a later clinical stage (<i>p</i> = 0.001). In patients receiving peri-immunotherapy radiotherapy, leukopenia was more frequent (<i>p</i> = 0.030). <b>Conclusion:</b> Baseline PIV is independently associated with the occurrence of irAEs in advanced NSCLC patients receiving first-line PD-1 inhibitor therapy. Adding bevacizumab or radiotherapy may modify safety profiles.},
DOI = {10.32604/or.2026.079813}
}